Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SMC

- PMLiVE

Gilead and Galapagos JAK contender scores in RA trial

Trial adds to rivalry with AbbVie

- PMLiVE

AbbVie to develop argenx-partnered GARP-targeted immunotherapy

Will build on an initial $60m deal with the biotech

- PMLiVE

AbbVie’s blockbuster-in-waiting for endometriosis gets FDA nod

First new oral treatment in more than 10 years

Roche Basel Switzerland

Roche keeps Venclexta train rolling with new leukaemia filing

The drug could treat AML patients who are ineligible for chemotherapy

- PMLiVE

Daily Brief: Europe changes mind on Puma drug, Pfizer’s Healthcare Hub, AbbVie and Calico add $1bn to anti-ageing quest

The latest from pharma, biotech and healthcare

- PMLiVE

AbbVie, Roche get FDA OK for broader use of Venclexta

The drug is tipped to become a $2.5bn product by 2024

- PMLiVE

AbbVie trial backs chemo-free Imbruvica combo regimen

Imbruvica paired with Roche’s Gazyva for previously untreated CLL patients

- PMLiVE

AbbVie’s upadacitinib aces phase III trial

Arthritis drug outperformed both placebo and Humira in the study

Biogen Idec building

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Agreement could see Europe access Imraldi as early as October this year

- PMLiVE

AbbVie slumps on trial results for would-be blockbuster Rova-T

The pharma group saw its shares plummet after the news broke

Biogen Idec building

Biogen and AbbVie pull MS drug Zinbryta from the market

Potential risks of liver damage and immune-related conditions have been reported

- PMLiVE

AbbVie reports more solid data for would-be psoriasis blockbuster

Risankizumab showed to be more effective in plaque psoriasis patients than J&J’s Stelara

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links